How to recruit lupus patients for clinical trials

How many Americans have lupus?

A CDC funded analysis of the National Lupus Registry network, published in Arthritis and Rheumatology in 2021, estimated about 204,295 Americans have systemic lupus erythematosus, a prevalence of 72.8 per 100,000 people (Lupus Research Alliance).

A simple ratio puts the competition in perspective. The CDC funded study reports 204,295 Americans with SLE. Divided across 93 recruiting studies, that is roughly 2,197 people per study nationally, before eligibility criteria, geography, and patient willingness cut the pool down. Most of those patients will never hear about a trial unless a physician brings it up.

Compare that with asthma, which has about 215,558 patients per recruiting study. Lupus is a small population with heavy sponsor interest. Industry leads 44 of the 74 recruiting interventional trials, and there are 21 Phase 1 studies. Every eligible patient is contested.

How many lupus trials are recruiting in the United States right now?

As of October 6, 2026, ClinicalTrials.gov lists 93 lupus studies with a status of recruiting and at least one location in the United States (ClinicalTrials.gov). Of those, 74 are interventional trials and 19 are observational studies. Industry is the lead sponsor on 49 of them, about 53%. Academic centers, cooperative groups, and government sponsors run the rest.

Interventional lupus trials by phase:

The median interventional trial targets 73 participants in total across all of its sites. The typical industry funded trial lists 10.5 recruiting locations in the United States, so each site is usually expected to deliver a small slice of that total, and sponsors notice quickly which sites deliver none.

Where are lupus trials concentrated?

Every location on every recruiting study counts here. Together the 93 studies list 768 recruiting US locations. These states host the most recruiting studies:

The most frequently listed institutions include Oklahoma Medical Research Foundation, Medical University of South Carolina, Columbia University Medical Center, and Hospital for Special Surgery. The industry sponsors with the most recruiting lupus trials right now include AstraZeneca, Fate Therapeutics, Novartis Pharmaceuticals, AbbVie, and EMD Serono Research & Development Institute. If your site sits in one of the top states, you are recruiting from the same patient population as several large academic programs at once, and the patients who reach you will mostly come through the physicians who already treat them.

Which physicians manage lupus patients?

• Rheumatologists, who diagnose and manage nearly all SLE patients. The AAMC counts 7,071 active rheumatologists (AAMC 2024 via Becker's).
• Nephrologists, for lupus nephritis studies. The AAMC counts 12,623 active nephrologists.
• Dermatologists, for cutaneous lupus studies.

With about 7,000 rheumatologists nationally, a site can realistically know every rheumatologist within driving distance by name. That is a list small enough to cover completely.

What decides eligibility in lupus trials?

Lupus protocols usually require a confirmed SLE diagnosis by classification criteria, a disease activity score above a threshold, positive autoantibodies, and stable background therapy. Lupus nephritis trials add biopsy and proteinuria requirements. Ask referring rheumatologists for recent serologies and the current treatment list. Screen failures average 36.3% across Phase 2 and 3 trials (Tufts CSDD), and in a small population every failed screen costs a patient another site could have enrolled. See rheumatoid arthritis trial referrals for working with rheumatology practices.

Why physician referral matters more than volume

A large patient population does not fill trials on its own. Physicians refer a median of about five patients into clinical trials per year, which is less than 0.2% of their annual patient volume (Getz, Applied Clinical Trials). In Tufts CSDD research, physicians and nurses named lack of access to study information and lack of time as the main reasons they do not refer, and physicians in clinical practice were 2.7 times more likely to refer than physicians in hospital settings (Tufts CSDD via Applied Clinical Trials).

That is the gap a site can close. The physicians who diagnose and manage your study population already know which patients are likely to qualify. They need a short, specific summary of your open study, a named coordinator, and a reason to believe the patient will come back to them.

A practical lupus referral plan for your site

1. Pull the live ClinicalTrials.gov list for your state and note which competing studies are enrolling the same population within driving distance of your site.
2. List the rheumatologists, nephrologists, and dermatologists within a realistic drive of your site. Community practices come first.
3. Send each physician a one page study summary: the diagnosis, the two or three criteria that decide most eligibility, what the patient will experience, and the coordinator's direct line.
4. Follow up by email and LinkedIn, and call the practices that engage.
5. Report back to the referring physician on every patient, whether or not the patient enrolls.

See how to get physicians to refer patients and the referral letter guide for templates.